D.E. Shaw & Co
KRTX

D.E. Shaw & Co’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

D.E. Shaw & Co’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,131
Closed -$6.06M – 4867
2023
Q4 		$6.06M Sell
19,131
-20,353
-52% -$3.96M 0.01% 1754
2023
Q3 		$6.68M Sell
39,484
-79,842
-67% -$15M 0.01% 1576
2023
Q2 		$25.9M Buy
119,326
+11,907
+11% +$2.55M 0.03% 741
2023
Q1 		$19.5M Sell
107,419
-169,761
-61% -$32.5M 0.02% 912
2022
Q4 		$54.5M Sell
277,180
-40,940
-13% -$8.78M 0.06% 401
2022
Q3 		$71.6M Buy
318,120
+312,660
+5,726% +$63.3M 0.09% 257
2022
Q2 		$691K Buy
+5,460
New +$628K ﹤0.01% 3868
2021
Q4 		– Sell
-16,285
Closed -$1.99M – 5803
2021
Q3 		$1.99M Sell
16,285
-964
-6% -$111K ﹤0.01% 3040
2021
Q2 		$1.97M Buy
+17,249
New +$2.02M ﹤0.01% 2957
2020
Q3 		– Sell
-7,211
Closed -$804K – 4253
2020
Q2 		$804K Buy
+7,211
New +$627K ﹤0.01% 3073
2020
Q1 		– Sell
-27,118
Closed -$2.04M – 4351
2019
Q4 		$2.04M Buy
+27,118
New +$1.19M ﹤0.01% 2451

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

D.E. Shaw & Co's KRTX Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 19,131 shares — an estimated $6.06M sold.

D.E. Shaw & Co first reported a position in KRTX in Q4 2019 and held it in 11 quarters. The position peaked at $71.6M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • D.E. Shaw & Co reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 19,131 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $6.06M.
  • D.E. Shaw & Co first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • D.E. Shaw & Co's Karuna Therapeutics, Inc. Common Stock position peaked at $71.6M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.